Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 10/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24427515 | 0.85 | SCN9A (0.41) | SCN9ASCN5ACDK8CDK19MAPK14 | |
| SCHEMBL24427514 | 0.75 | PDPK1 (0.52) | KDRSYKAURKB | |
| SCHEMBL24427520 | 0.74 | SCN9A (0.45) | SCN9ASCN5ACDK8CDK19AKT1 | |
| SCHEMBL24427251 | 0.73 | MAPK14 (0.39) | CDK8MAPK14KDRFLT3AURKB | |
| SCHEMBL17832298 | 0.71 | KDM4E (0.42) | MAPK14 | |
| SCHEMBL9181218 | 0.71 | SCN9A (0.48) | SCN9ASCN5AKDR | |
| SCHEMBL21000228 | 0.70 | DDB1 (0.49) | SCN9ASCN5AAKT1KDRDDB1 | |
| SCHEMBL24427244 | 0.70 | MPL (0.40) | FLT3 | |
| SCHEMBL24428023 | 0.70 | CREBBP (0.37) | FLT3 | |
| SCHEMBL20481791 | 0.69 | SCN9A (0.60) | SCN9ASCN5ACDK8CDK19AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD. (CN) | 2022-12-06 | — | — | US | disclosed |
| EP-3998263-A1 | TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11518766-B2 | Tricyclic compound, preparation method therefor and use thereof | TFPI, TFPI2, F11 | SCN9A 1993/4885SCN5A 1717/4885CDK8 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.